Hennion & Walsh Asset Management, Inc. Inovio Pharmaceuticals, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$0.38 - $0.58 $12,270 - $18,728	-32,291 Reduced 16.49%	163,562 $63,000
Q2 2023 Aug 09, 2023	SELL	$0.39 - $0.94 $72,658 - $175,126	-186,305 Reduced 48.75%	195,853 $87,000
Q1 2023 Apr 20, 2023	SELL	$0.79 - $1.91 $8,694 - $21,021	-11,006 Reduced 2.8%	382,158 $313,000
Q4 2022 Jan 12, 2023	BUY	$1.41 - $2.5 $57,024 - $101,107	40,443 Added 11.47%	393,164 $613,000
Q3 2022 Nov 14, 2022	SELL	$1.66 - $2.79 $14,068 - $23,645	-8,475 Reduced 2.35%	352,721 $608,000
Q2 2022 Jul 19, 2022	BUY	$1.44 - $3.98 $22,505 - $62,203	15,629 Added 4.52%	361,196 $625,000
Q1 2022 Apr 26, 2022	BUY	$2.97 - $5.2 $210,466 - $368,492	70,864 Added 25.8%	345,567 $1.24 Million
Q4 2021 Feb 14, 2022	BUY	$4.99 - $7.46 $568,271 - $849,559	113,882 Added 70.81%	274,703 $1.37 Million
Q3 2021 Nov 12, 2021	BUY	$7.16 - $9.69 $394,100 - $533,356	55,042 Added 52.03%	160,821 $1.15 Million
Q2 2021 Aug 13, 2021	BUY	$6.23 - $10.03 $659,003 - $1.06 Million	105,779 New	105,779 $981,000

281K

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $456M
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.